Use of melatonin and/or inflammatory body inhibitors in the preparation of drugs for treating of pulmonary hypertension

Abstract

The invention relates to the field of medical treatment and health care, in particular to the application of melatonin and / or inflammatory body inhibitors in the preparation of drugs for treating pulmonary hypertension. The invention utilizes hypoxia to induce mice to produce pulmonary artery hypertension, mice are then treated with melatonin and inflammatory body inhibitor alone or in combination, the right ventricular hypertrophy index, right ventricular systolic blood pressure and pulmonary pathology are observed, and the effect of melatonin on the pathological development of pulmonary hypertension is confirmed by statistics of vascular remodeling rate, and the effect of melatonin on inflammatory bodies is verified by in vitro cells. The results show that melatonin and inflammatory bodyinhibitor have good therapeutic effect on pulmonary hypertension, and could significantly reduce right ventricular systolic blood pressure, inhibit the activation of inflammatory body, and achieve the purpose of treating pulmonary hypertension. At the same time, the combination of melatonin and inflammatory body inhibitor has more significant effect.

Description

technical field [0001] The invention relates to the field of medical care, in particular to the application of melatonin and / or inflammasome inhibitors in the treatment of pulmonary arterial hypertension. Background technique [0002] Pulmonary hypertension (PH) is a disease or pathophysiological syndrome in which the pressure in the pulmonary artery is abnormally increased due to known or unknown reasons. There are pulmonary circulation disorders and high right heart load, which can lead to right heart failure and even death. Pulmonary hypertension is common in clinical practice and is a health care problem that seriously endangers people's health. Arterial hypertension is a very serious disease. 75% of the patients were concentrated in the 20-40 age group, and 15% of the patients were under the age of 20. Symptoms of pulmonary hypertension include: shortness of breath, fatigue easily, fainting, chest pain, and swelling in the legs and ankles. In addition, cardiac auscul...

AI Technical Summary

Problems solved by technology

Some anticoagulant drugs, diuretics, digitalis, and supportive treatments such as oxygen inhalation are not effective

Some targeted drugs have been gradually developed in recent years, such as bosentan, ambrisentan, iloprost, etc. Most of them are aimed at patients with type 1 and 4 pulmonary arterial hypertension, with many adverse reactions and high risks

However, interventional therapy and surgical therapy are only for a small number of patients with pulmonary arterial hypertension, and the risk is high, and there are many sequelae after surgery.

Images